daratumumab,talquetamab,teclistamab
merck,janssen,genmab
['mmsm', 'redirectt-1', ' emd ']
more data with updated followup from redirectt-1. orr 87% for all dose levels and 96% at rp2r. median pfs 21 months for all dose levels. is that better than what would be seen with sequential therapy? emd dz benefitted but median pfs still short (10 months). #mmsm #asco23 
Asst Professor at University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QRrW